TWI508966B - 三衍生物 - Google Patents

三衍生物 Download PDF

Info

Publication number
TWI508966B
TWI508966B TW103115365A TW103115365A TWI508966B TW I508966 B TWI508966 B TW I508966B TW 103115365 A TW103115365 A TW 103115365A TW 103115365 A TW103115365 A TW 103115365A TW I508966 B TWI508966 B TW I508966B
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
group
methyl
Prior art date
Application number
TW103115365A
Other languages
English (en)
Chinese (zh)
Other versions
TW201506027A (zh
Inventor
Thomas Allen Chappie
Christopher John Helal
Bethany Lyn Kormos
Jamison Bryce Tuttle
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW201506027A publication Critical patent/TW201506027A/zh
Application granted granted Critical
Publication of TWI508966B publication Critical patent/TWI508966B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW103115365A 2013-05-02 2014-04-29 三衍生物 TWI508966B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02

Publications (2)

Publication Number Publication Date
TW201506027A TW201506027A (zh) 2015-02-16
TWI508966B true TWI508966B (zh) 2015-11-21

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103115365A TWI508966B (zh) 2013-05-02 2014-04-29 三衍生物

Country Status (33)

Country Link
US (3) US8933224B2 (enExample)
EP (1) EP2991989B1 (enExample)
JP (1) JP6263606B2 (enExample)
KR (1) KR101770905B1 (enExample)
CN (1) CN105164134B (enExample)
AP (1) AP2015008843A0 (enExample)
AR (1) AR096161A1 (enExample)
AU (1) AU2014261070A1 (enExample)
BR (1) BR112015027760A8 (enExample)
CA (1) CA2910759C (enExample)
CL (1) CL2015003037A1 (enExample)
CR (1) CR20150591A (enExample)
CU (1) CU20150144A7 (enExample)
DK (1) DK2991989T3 (enExample)
DO (1) DOP2015000271A (enExample)
EA (1) EA027936B1 (enExample)
EC (1) ECSP15050110A (enExample)
ES (1) ES2637816T3 (enExample)
GE (1) GEP201706675B (enExample)
MA (1) MA38559B1 (enExample)
MD (1) MD20150103A2 (enExample)
MX (1) MX2015015163A (enExample)
NI (1) NI201500157A (enExample)
NZ (1) NZ712949A (enExample)
PE (1) PE20151940A1 (enExample)
PH (1) PH12015502462A1 (enExample)
SG (1) SG11201508201VA (enExample)
TN (1) TN2015000490A1 (enExample)
TW (1) TWI508966B (enExample)
UA (1) UA111696C2 (enExample)
UY (1) UY35547A (enExample)
WO (1) WO2014177977A1 (enExample)
ZA (1) ZA201508968B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20150103A2 (ro) * 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
KR20220087474A (ko) * 2019-10-21 2022-06-24 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
CN117486878B (zh) * 2023-10-27 2026-05-05 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
CN121159397A (zh) * 2025-09-18 2025-12-19 江西芜锂增致循环科技有限公司 一种应用于高钠锂比卤水中提锂的硝基化β-双酮萃取剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201127840A (en) * 2009-10-30 2011-08-16 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
TW201200519A (en) * 2010-03-09 2012-01-01 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use as PDE10 inhibitors
TW201247673A (en) * 2011-02-23 2012-12-01 Pfizer Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8207370B2 (en) 2006-09-26 2012-06-26 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
US20130071415A1 (en) 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
MD20150103A2 (ro) * 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201127840A (en) * 2009-10-30 2011-08-16 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
TW201200519A (en) * 2010-03-09 2012-01-01 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use as PDE10 inhibitors
TW201247673A (en) * 2011-02-23 2012-12-01 Pfizer Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders

Also Published As

Publication number Publication date
CA2910759C (en) 2018-01-16
UY35547A (es) 2014-11-28
TW201506027A (zh) 2015-02-16
ES2637816T3 (es) 2017-10-17
US20150353579A1 (en) 2015-12-10
CL2015003037A1 (es) 2016-04-22
CR20150591A (es) 2016-01-04
MX2015015163A (es) 2016-02-22
CN105164134A (zh) 2015-12-16
US20150080401A1 (en) 2015-03-19
PH12015502462A1 (en) 2016-02-22
GEP201706675B (en) 2017-05-25
CU20150144A7 (es) 2016-04-25
NI201500157A (es) 2015-11-30
EA027936B1 (ru) 2017-09-29
US9145427B2 (en) 2015-09-29
EP2991989A1 (en) 2016-03-09
KR101770905B1 (ko) 2017-08-23
PE20151940A1 (es) 2016-01-21
NZ712949A (en) 2017-04-28
CN105164134B (zh) 2017-09-22
HK1213885A1 (zh) 2016-07-15
CA2910759A1 (en) 2014-11-06
US9296761B2 (en) 2016-03-29
BR112015027760A8 (pt) 2018-05-08
WO2014177977A1 (en) 2014-11-06
AU2014261070A1 (en) 2015-10-29
US20140329820A1 (en) 2014-11-06
DOP2015000271A (es) 2016-02-29
TN2015000490A1 (fr) 2017-04-06
MD20150103A2 (ro) 2016-02-29
SG11201508201VA (en) 2015-11-27
ZA201508968B (en) 2017-11-29
MA38559B1 (fr) 2018-04-30
EP2991989B1 (en) 2017-06-28
UA111696C2 (uk) 2016-05-25
JP6263606B2 (ja) 2018-01-17
DK2991989T3 (en) 2017-07-31
US8933224B2 (en) 2015-01-13
EA201591819A1 (ru) 2016-05-31
ECSP15050110A (es) 2017-08-31
JP2016517877A (ja) 2016-06-20
AR096161A1 (es) 2015-12-09
KR20160003234A (ko) 2016-01-08
AP2015008843A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
JP5546693B2 (ja) ピラゾロキノリン誘導体
CN105164134B (zh) 作为pde10抑制剂的咪唑并‑三嗪衍生物
TWI643857B (zh) 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
CN104395315B (zh) 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
KR101864561B1 (ko) Jak 억제제
RS65419B1 (sr) Derivati pirazolila korisni kao sredstva protiv kancera
KR20160012194A (ko) 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
TW200938201A (en) Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
TW201200515A (en) Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors
US20230374015A1 (en) Inhibitors of fibroblast growth factor receptor kinases
HK1213885B (en) Imidazo-triazine derivatives as pde10 inhibitors
HK40130962A (en) Trem2 agonists
OA17580A (en) Imidazo-Triazine derivatives as PDE 10 inhibitors.
TW201524972A (zh) 咪唑衍生物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees